BCRP has been suggested to be closely associated with resistance of NSCLC to topoisomerase I inhibitors, including irinotecan and its active metabolite, SN-38 [9], while MRP2 contributes to cisplatin resistance [10]. Here, ABCG2 is linked to non-small cell lung carcinoma.